News | August 27, 2025
SMS Pharmaceuticals receives EIR from USFDA for Central Laboratory Analytical Services
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
The inspection concluded with zero Form 483 observations
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
This is the second US FDA GMP inspection of this facility within one year
The company will be submitting the responses to US FDA observations within stipulated timeline
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Subscribe To Our Newsletter & Stay Updated
